Am J Pathol 2003, 163:1101–1107 PubMedCrossRef

Am J Pathol 2003, 163:1101–1107.PubMedCrossRef PFT�� solubility dmso 34. Lee S, Lee HJ, Kim JH, Lee HS, Jang JJ, Kang GH: Aberrant CpG island hypermethylation along multistep

hepatocarcinogenesis. Am J Pathol 2003, 163:1371–1378.PubMedCrossRef 35. Massinen S, Hokkanen ME, Matsson H, Tammimies K, Tapia-Páez I, Dahlström-Heuser V, Kuja-Panula J, Burghoorn J, Jeppsson KE, Swoboda P, Peyrard-Janvid M, Toftgård R, Castrén E, Kere J: Increased expression of the dyslexia candidate gene DCDC2 affects length and signaling of primary cilia in neurons. PLoS One 2011, 6:e20580.PubMedCrossRef 36. Giles RH, van Es JH, Clevers H: Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003, 1653:1–24.PubMed 37. Wong CM, Fan ST, Ng IO: Beta-catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer 2001, 92:136–145.PubMedCrossRef 38. Shih YL, Shyu RY, Hsieh CB, Lai HC, Liu KY, Chu TY, Lin YW: Promoter methylation of the secreted frizzled-related protein 1 gene SFRP1 is frequent in hepatocellular carcinoma. Cancer 2006, 107:579–590.PubMedCrossRef 39. Nomoto S, Kinoshita T, Kato K, Otani S, Kasuya H, Takeda S, Kanazumi N, Sugimoto H, Nakao A: Hypermethylation of multiple genes as clonal markers in multicentric hepatocellular carcinoma. Br J Cancer 2007,

97:1260–1265.PubMedCrossRef 40. Shih YL, Hsieh CB, Lai HC, Yan MD, Hsieh TY, Chao YC, Lin YW: SFRP1 Suppressed hepatoma cells growth through Wnt canonical signaling pathway. Int J Cancer 2007, 121:1028–1035.PubMedCrossRef 41. Kaur Savolitinib order P, Mani S, Cros MP, Scoazec JY, Chemin I, Hainaut P, Herceg Z: Epigenetic silencing of sFRP1 activates the canonical Wnt pathway and contributes to increased cell growth and proliferation in hepatocellular

carcinoma. Tumour Biol 2012, 33:325–336.PubMedCrossRef 42. Gallinari P, Di Marco S, Jones P, Pallaoro M, Steinkühler C: HDACs, histone deacetylation and gene transcription: from molecular Celecoxib biology to cancer therapeutics. Cell Res 2007, 17:195–211.PubMed 43. Su Z, Xia J, Zhao Z: Functional complementation between transcriptional methylation regulation and AMN-107 mw post-transcriptional microRNA regulation in the human genome. BMC Genomics 2011,12(5):S15.PubMedCrossRef 44. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R 3rd, Shen L, Nimer SD, Leavitt R, Raza A, Saba H: Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006, 106:1794–1803.PubMedCrossRef 45. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Köhler G, Wijermans P, Jones PA, Lübbert M: Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 2002, 100:2957–2964.PubMedCrossRef Competing interests The authors declare that they have no competing interests.

This entry was posted in Antibody. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>